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Background: Adenosine is known as a protective and anti-inflammatory nucleoside. Angiotensin II is the main
hormone of the renin-angiotensin system. It is associated with endothelial permeability, recruitment, and activation
of the immune cells through induction of inflammatory mediators. Matrix metalloproteinase-9 (MMP-9) plays an
important role in inflammatory processes mediated by macrophages.
Objectives: Investigate whether adenosine pretreatment modulates angiotensin II-induced MMP-9 expression
and activation of signaling molecules.
Methods: Human monocytic U-937 cells were treated with either adenosine or angiotensin II alone or angiotensin
II following a pretreatment with adenosine. Supernatants were analyzed for MMP-9 activity by zymography
method. MMP-9 gene expression was analyzed using real-time PCR. Activation of inflammatory mediators IκB-α,
NF-κB, JNK, p38 MAPK, and STAT3 were analyzed by a multi-target ELISA kit. Association of Protein kinase A
(PKA) in adenosine effects was studied by pre-incubation with H89, a selective PKA inhibitor.
Results: Treatment of the cells with angiotensin II significantly increased MMP-9 production (p <0.05). Adenosine
pretreatment did not attenuate this angiotensin II effect. Angiotensin II treatment induced NF-κB, JNK and p38
activation. Pretreatment with adenosine prior to angiotensin II stimulation showed a 40% inhibitory effect on p38
induction (p <0.05). This effect was reversed by PKA inhibition.
Conclusion: The present data confirmed that monocytic MMP-9 was a target gene for angiotensin II. Adenosine
pretreatment did not inhibit MMP-9 increase in response to angiotensin II. However, it showed a potential
inhibitory effect on angiotensin II inflammatory signaling.
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Adenosine is an endogenous immunomodulator
nucleoside that exhibits anti-inflammatory and
immune-suppressive properties [1]. Its extra-cellular
levels rise rapidly in conditions of ischemia, hypoxia,
inflammation, and trauma in which the immune system
has a paramount role [2]. The effects of adenosine
are mediated through its four receptors (A1, A2A, A2B,
and A3). It has been reported that a variety of
protective mechanisms such as modulation of cytokine
production by macrophages, attenuation of free radical
generation, prevention of mitochondrial damage
and increasing oxygen supply/demand ratio are
associated with adenosine [3, 4]. Adenosine activates
cyclic-adenosine monophosphate (cAMP)/protein
kinase A (PKA) pathway through binding to its A2A
receptor that is known as a common inhibitory pathway
of adenosine [5].
Angiotensin II is considered as the primary
effector of the renin-angiotensin system. It can
potentially affect all vascular cells such as endothelial
cells, smooth muscle cells (SMCs), fibroblasts,
monocyte/macrophages, and myocytes [6]. In
pathological states, angiotensin II promotes
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hypertension, endothelial dysfunction, and vascular
inflammation [7]. In the vascular wall, dysregulated
function of specialized enzymes, called matrix
metalloproteinases (MMPs), leads to impaired
endothelial barrier function and infiltration of
inflammatory cells [8]. Matrix metalloproteinase-9
(MMP-9) plays an important role in inflammatory
processes mediated by macrophages [9].
It has been demonstrated that angiotensin II up-
regulates MMP expression via signaling cascades that
are different in cell types [10]. Angiotensin II type 1
receptor (AT1R) stimulation activates G protein and
non-G protein related signaling pathways. It further
activates mitogen-activated protein kinases (MAPK),
receptor and non-receptor tyrosine kinases, Janus
family kinases-signal transducers and activators of
transcriptions (JAK-STATs), small G proteins (Ras,
Rho, Rac, etc) and NADPH oxidase [6, 11]. Among
signaling molecules of angiotensin II, nuclear factor-
kappa B (NF-κB), Rho kinases, Jun N-terminal kinase
(JNK), p38 MAPK, STAT3 and reactive oxygen
species (ROS) represent convergent points and key
regulatory proteins in signaling pathways controlling
the stress and inflammation responses  [6, 12].
Multiple approaches such as immunosuppressive
therapy and drugs against downstream targets
of angiotensin II AT1 receptor signaling have been
proposed to modulate the effects of angiotensin [13].
In this study, we hypothesized that adenosine can
modulate the effects and signaling mediators of
angiotensin II. To test this hypothesis, we studied the
effects of angiotensin II on MMP-9 expression and
activity, either with or without adenosine pretreatment
in a monocytic cell line model. Further, we studied the
activation of key inflammatory signaling mediators in
response to either angiotensin II or adenosine alone
following a pretreatment with adenosine. Pre-
incubation with H89, a pharmacologic protein kinase
A inhibitor, was performed to elucidate PKA




Adenosine, angiotensin II, lipopolysaccharide
(LPS) from Escherichia coli 055:B5, gelatin, and
α-tocopherol were purchased from Sigma (Saint
Louis, USA). H89 dihydrochloride (protein kinase A
inhibitor) was purchased from Tocris Bioscience
(Bristol, UK). Cell culture reagents were purchased
from Gibco (Invitrogen, USA).
Cell culture
The monocytic U-937 cell line was obtained from
the cell bank of Pasteur Institute of Iran (NCBI). Cells
were grown in RPMI-1640 containing 10% fetal
bovine serum (FBS), 100 IU/mL penicillin, and
100 μg/mL streptomycin at 37οC in a humidified
atmosphere of 5% CO2 and 95% air. Cultures were
provided with fresh media every two to three days.
Cells were seeded in 12-well plates at a density of
1x106 cells/mL in a low serum medium (1%) and
treated with LPS (100 ng/mL), adenosine (100 μM)
and angiotensin II (100 nM) in combination with H89
(10 μM). Pretreatment with adenosine was performed
15 minutes prior to angiotensin II treatment. In case
of PKA inhibition, cells were pre-incubated with 10
μM H89 for one hour prior to adenosine exposure.
Zymography
Assessment of MMP-9 activity in the culture media
was performed by zymography method as previously
described [14]. Briefly, samples of conditioned media
were equally loaded on sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) containing 0.1%
gelatin type B. Electrophoresis was run under non-
reducing conditions. Gels are washed in 2.5 % Triton
X-100 twice for 30 minutes and incubated in substrate
buffer (50 mM Tris-HCl, 5 mM CaCl2, 0.01% NaN3,
pH 7.6) for 24 hours at 37οC. Gels were then stained
with 1% coomassie blue R250 for one hour and were
destained (45% methanol, 10% acetic acid). Gels were
photographed, and the detected zymogram bands were
analyzed by NIH ImageJ software based on the mean
area density calculation in a grey-scale format.
Real-time polymerase chain reaction (PCR)
This technique was applied to analyze MMP-9
gene expression  following  adenosine  and  angiotensin
II  treatments.  FAST  Pure  RNA  extraction  kit
(Takara Bio, Kyoto, Japan)  was  employed  to  isolate
RNA  from  1x106  cells. Synthesis of cDNA carried
out  at  37οC  for  30  minutes  using  the Primescript
RT  enzyme  from  Takara.  Real-time  PCR  reactions
performed  using  specific  primer  pairs  and  Taqman
probes  (Alpha  DNA, Montreal,  Canada). They  are
cited  in  RTPrimer  data  base  with  the  following
sequences:  MMP-9  forward 5'-ACC TCG AAC
TTT GAC AGC GAC-3', reverse 5'-GAG GAA
TGA TCT AAG CCC AGC-3', probe  FAM 5' -TGC
CCG GAC CAA GGA TAC AGT TTG TT-3'
TAMRA, GAPDH forward 5'-GTG AAC CAT GAG
     723Modulation of angiotensin II effects by adenosineVol. 4 No. 5
October 2010
AAG TAT GAC AAC-3', reverse 5'-CAT GAG TCC
TTC CAC GAT ACC-3', and  probe  FAM 5'-  CCT
CAA GAT CAT CAG CAA TGC CTC CTG-3'
TAMRA. Reactions completed using  Rotor-gene
6000  thermocycler  (Corbett Res, Sydney, Australia)
in  a  total  volume  of  20 μL, containing  2 μL cDNA,
10 μL  Premix  Ex-Taq  (Takara Bio, Kyoto, Japan)
and  0.2 μM of each primer and  probe. MMP-9 gene
expression was normalized against GAPDH
expression. Relative quantification analysis was
performed  using  Rotor-gene  6000  software,  version
1.7  based  on  ΔΔCt calculations.
Signaling analysis
A multi-target ELISA kit (Cell Signaling
Technology, Danvers, USA) was used to assay
phospho-inhibitor of kappa-B (phospho-IκB-α),
NF-κB, phospho-NF-κB, phospho-JNK, phospho-p38
MAPK, and phospho-STAT3 following treatment
with either adenosine or angiotensin II alone or
angiotensin II following treatment with adenosine.
After proper incubation times (five minutes for
phospho-IκB-α, 10 minutes for NF-κB, phospho-
NF-κB, and phospho-STAT3 or 15 minutes for
phospho-JNK and phospho-p38), cells were washed
with ice-cold PBS (phosphate buffered saline). Lysis
buffer was applied and maintained on ice for five
minutes followed by sonication and centrifugation.
Supernatants were diluted and loaded to the
corresponding ELISA wells. The assay procedure was
performed according to the manufacturer’s protocol.
To dilute the lysates properly and to assure that equal
amounts of protein were loaded in the wells, lysates
were assayed for protein content using Lowry’s
reagents (Pierce, Rockford, USA).
Cytotoxicity assay
A  cytotoxicity  detection  kit  (Roche,  Germany)
was  used  to  study  cytotoxic  effects  of  angiotensin
II,  adenosine,  and H89  on  U-937 cells. 1x104  cells
were seeded in 96-well plates  and  incubated with
treating agents for 18 hours. Lactate  dehydrogenase
(LDH)  activities  in the  conditioned  media  were
assayed as indicators of cell damage. The
cytotoxicity  percentage was calculated  by  comparing
the  amount  of  released  LDH  following  treatment
to the maximum release of LDH achieved by
application  of  lysis  solution  to  the  control  cells.
Statistical analysis
The data are presented as mean ± standard error
of means (SEM) of four independent determinations.
Results of different groups were analyzed using
ANOVA followed by Tukey multiple comparison tests.
Differences with a p-value of < 0.05 were considered
significant.
Results
Increased MMP-9 expression and activity by
angiotensin II
To  investigate  the  effects  of  adenosine  and
angiotensin  II  alone  and  in  combination  on  MMP-
9  production,  we  applied  zymography  and  real-
time  PCR  techniques.  As  shown  in  Fig. 1,  Cultured
U-937  cells  constitutively  demonstrated  MMP-9
activity.  Treatment  of  the  cells  with  angiotensin  II
for  24  hours  significantly  increased  MMP-9  activity
in  the  supernatents  (50%, p <0.05).  Adenosine
did  not  show  any  effect  on  gelatinolytic  activity
of  MMP-9.  Pretreatment  with  adenosine  did  not
inhibit  the  stimulatory  effect of angiotensin  II.  LPS,
which  was  applied  in  the  experiments  as  a  positive
control,  substantially  induced  MMP-9  activity  (94%,
p <0.01).
MMP-9 gene expression was analyzed by real-
time PCR.  As  shown  in  Fig. 2,  incubation  of  cells
with  angiotensin  II  for  12  hours  induced  2.6-folds
increase  in  MMP-9 gene  expression  (p <0.05),  but
no change in MMP-9 gene  expression  was  observed
following adenosine  treatment.  Pretreatment  of  cells
with  adenosine  prior  to  challenging  with  angiotensin
II did  not attenuate its stimulatory  effect on
MMP-9.
Inhibition of angiotensin II-induced  p38  MAPK
activation by adenosine  pretreatment
To  investigate  the  activation  of  key  pro-
inflammatory  signaling  mediators  after  angiotensin
II  treatment,  a  commercial  Path-scan  ELISA
kit  was  used. Possible modulatory  effects  of
adenosine pretreatments  on  these signaling  mediators
was  also  assessed  with  the  same  ELISA  kit.  As
shown  in  Fig. 3,  basal  levels  of  unphosphorylated
NF-κB and  phospho-STAT3  did  not  change
following  angiotensin  II  and  adenosine  treatments.
This indicates  that  expression  of  NF-κB  and
activation  of  STAT3  could  not  be  associated  with
MMP-9 up-regulation. Angiotensin II  significantly
induced  NF-κB, JNK and p38  activation  within
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15 minutes (4.8, 3.8 and 3.2-folds  increase,
respectively, in  relative  to  control, p <0.01). In  non-
stimulated  conditions,  phosphorylated  levels  of  these
intermediates were  insignificant  and  adenosine
treatment alone did not change their levels.
Pretreatment  of  the  cells  with  adenosine  before
angiotensin II  stimulation  showed  a  considerable
inhibitory  effect  on  p38  activation  (40%  reduction
in phospho-p38  compare  to  angiotensin  II  stimulated
state,  p <0.05). The inhibition was not statistically
significant for phospho-NF-κΒ and phospho-JNK.
IκB-α  is  an  intracellular inhibitor of NF-κB,
dissociates from NF-κB following phosphorylation,
leading to NF-κB activation.  Angiotensin II treatment
increased phospho-IκB-α  level  which could not be
modulated  by adenosine pretreatment. However, the
observed increase was not statistically significant
(p <0.1).
Suppression of p38 MAPK by adenosine
pretreatment
Protein kinase A is the main kinase in mediating
anti-inflammatory effects of adenosine A2A receptor.
To investigate possible PKA contribution in the
inhibitory effect of adenosine on p38, a pharmacologic
inhibitor of PKA, H89, was applied in combination
with adenosine and angiotensin II. H89 pre-incubation
did not alter angiotensin II stimulated phospho-p38
level, but it reversed the inhibitory effect of adenosine
on angiotensin II-induced phospho-p38 activation up
to 74% (p <0.05) (Fig. 4). H89 did not affect phospho-
p38 level following one hour of incubation.
Fig. 1 Determination of MMP-9 activity in conditioned media of U-937 cells using zymography method. 1x106 serum
starved cells were seeded in 12-well plates and treated either with LPS (100 ng/mL), adenosine (100 μM), angiotensin
II (100 nM) or adenosine+angiotensin II for 24 hours. Pretreatment with adenosine was made for 15 minutes prior to
angiotensin II exposure. A representative zymogram is shown (upper panel). The data are presented in relative to
control as mean ± SEM (n=4) following densitometry. *p <0.05 vs. control. ADO = adenosine, ANG = angiotensin II,
LPS = lipopolysaccharide.
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Fig. 2 Analysis of MMP-9 mRNA gene expression using real-time PCR. 1x106 serum starved cells were seeded in 12-well
plates and incubated with LPS (100 ng/mL), adenosine (100 μM), angiotensin II (100 nM) or adenosine+angiotensin
II for 12 hours. Pretreatment with adenosine was made for 15 minutes prior to angiotensin II exposure. Relative MMP-
9 gene expression data are presented as mean ± SEM (n=4). *p <0.05 vs. control. ADO = adenosine, ANG = angiotensin
II, LPS = lipopolysaccharide.
Fig. 3 Relative levels of signaling mediators of stress and inflammatory pathways following treatments. U-937 cells
were cultured in a low serum medium at a density of 1x106 cells/mL and treated either with adenosine (100 μM),
angiotensin II (100 nM) or adenosine+angiotensin II. Pretreatment with adenosine was performed for 15 minutes
before challenging with angiotensin II. Following relevant incubation time (five minutes for p-IκB, 10 minutes for
NF-κB, p-NF-κB and p-STAT3 and 15 minutes for p-JNK and p-p38) cells were lyzed and assayed for their protein
content. Signaling mediators in cell lysates were determined using a multi-target ELISA kit. Lysates were assayed at
a protein concentration of 0.5 mg/mL. Data are normalized against non-stimulated levels of analyte and represent the
mean ± SEM (n=4). *p <0.01 vs. control, # p <0.05 vs. angiotensin II treated. ADO = adenosine, ANG = angiotensin II.
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Cytotoxic effects of  treatments
     According to the results of LDH activity assay
following treatments with adenosine, angiotensin II
and H89 alone and in combination, none of them
significantly elevated LDH leakage from the cells
(Table 1). This indicates that none of them exerted
cytotoxic effects at the applied concentrations.
Discussion
There  are  emerging  concepts  of  regulation
of  angiotensin II function through receptor
modification,  receptor  complex  formation,  receptor
antibodies,  and  immunosuppressive  therapy  [13].
In  this  study,  we  benefited  from  adenosine  as  an
immunosuppressive and anti-inflammatory  metabolite
to  modulate  angiotensin  II  functions. Adenosine
has protective and anti-inflammatory properties. It has
been  shown  that  adenosine  can  modulate  MMP
secretion. Ernes  et  al. [15] showed  that  adenosine
inhibited MMP-9  secretion  in  neutrophiles  via
cAMP/PKA/Ca2+  pathway.  In  the study  by Zhao
et al. [16], hypoxia-mediated  suppression  of  MMP-
9  production  was  dependent  on  adenosine  cAMP/
PKA  signaling  pathway.
To  investigate  the modulatory effects of
adenosine  on  angiotensin  II  signaling  and  MMP-
9  expression,  we  employed  U-937  cells,  a  human
monocytic  cell  line.  There have been reports on  the
application  of  U-937  cell  line  to  study  suppressive
effects  of  adenosine  on  inflammatory  cytokine
production  [17].  Monocytes  are  important  target
cells  of  angiotensin II expressing  both  AT1 and  AT2
receptors. They have  substantial  roles in  promoting
vascular  inflammation, foam cell formation, and
MMP-9  secretion  [18, 19].  Yuan et al. [20] used
U-937  cells to investigate  the  inhibitory effect  of
angiotensin II  type  1  receptor  blockade  on  IL-
1beta  production.  U-937  cells  were  treated  with
Fig. 4 The effects of pharmacologic PKA inhibition on p38 modulation by adenosine and angiotensin II. Cells were
pre-incubated with 10 μM H89 for one hour followed by adenosine (100 μM, 15 minutes) and /or angiotensin
II (100 nM) treatments. After 15 minutes of incubation, cells were lyzed and assayed for phospho-p38 using Path-
Scan ELISA kit. Data are expressed in relative to non-stimulated control as mean ± SEM (n=4).  *p <0.01 vs. control,
#p <0.05 vs. angiotensin II treated, **p <0.05 vs. adenosine+angiotensin II treated. ADO = adenosine,
ANG = angiotensin II.
Table 1. Cytotoxicity potentials of the drugs applied in the treatments.
%Cytotoxicity 5.9 ± 1.0 2.0 ± 0.9 5.4 ± 0.5 1.3 ± 0.6 5.0 ± 1.9
P-value 0.05 0.85 0.08 0.97 0.13
Drug ADO ANG ADO+ANG H89 H89+ADO+ANG
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adenosine rather than specific agonists to activate its
receptors globally. Monocyte-macrophages express
all four  adenosine  receptor  types.
     In  this  study,  we  obtained  harmonious  data
from  zymography  and  gene  expression  experiments
in  which  angiotensin  II  stimulation  significantly
augmented MMP-9 expression  and  activity.
Adenosine pretreatment did not  significantly  inhibit
the  stimulatory  effect  of angiotensin  II on MMP-9.
Conclusions  on  the  modulatory  effects  of  adenosine
should  be  made  with  caution,  since  in  experiments
studying anti-inflammatory and protective
characteristics  of  adenosine,  multiple  variables
have  been  shown to influence  the  outcome.  These
variables  include  cell  type,  density  and  type  of
involved  receptor,  different  EC50  (concentration  of
agonist giving half maximal effect)  values  of  receptor
types, functionality of the intracellular signaling,
specificity of the analogs  employed,  adenosine
concentration, pre-exposure to inflammatory
cytokines, and the abundance of adenosine
metabolizing  enzymes  [21, 22, 23].  In a study by
Velot et  al. [24], it was  shown  that  adenosine
activated  MMP-9  secretion  by  macrophages
through  their  A3  receptors. This  finding  is  in  sharp
contrast  to  the  previous  observations by Ernes
et  al. [15]  and  Zhao  et  al.  [16] who  had  shown
adenosine  inhibited  MMP-9  secretion  through  its
A2A  receptors.
To  investigate  signaling,  we  employed  a  Path-
Scan  ELISA  kit  to measure the  activation  of  major
inflammatory  signaling  effectors,  namely  IκB-α,
NF-κB,  JNK,  p38  MAPK  and  STAT3.  Based  on
earlier  studies,  adenosine modulates  these  mediators
during  suppression  of  inflammation.  It  has  been
demonstrated  that  adenosine  can  suppress  activation
of  NF-κB  in  different  cell  types  [25].  It  has  also
been  reported  that  adenosine  A2A  receptor  signaling
regulates  NADPH  oxidase  activity  and  reactive
oxygen  species  (ROS)  formation  [26].  Adenosine
is a negative regulator of MAP kinase  signaling  [27].
Adenosine  inhibits  cytokine  receptor  activation  of
JAK-STAT  pathway  via  induction  of  suppressor
of  cytokine  signaling-3  (SOCS-3)  transcription  [28].
Another  mechanism  of  adenosine  protection  is
through  modulation  of  intracellular  calcium  release
and  suppression  of  calcium  signaling  [29].
Our  results  showed  that  angiotensin  II
treatment  increased  activation  of  NF-κB,  JNK
and  p38.  The  activation  of  NF-κB  and  JNK  may
account  for  the up-regulation of MMP-9  in  response
to angiotensin  II. Phosphorylated  JNK  and  p38
form  active  transcription  factor  activator  protein-1
(AP-1).  In  the  promoter  region  of  MMP-9,  there
are  binding elements for NF-κB, AP-1,  Ets-1  and
STAT  transcription  factors  [30]. Upon  activation of
gene  expression,  MMP-9  exerts  its activity  via
degradation  of  matrix  proteins.  The  lysis  of  matrix
proteins  in  endothelium  is  considered  as  a  prominent
initiator  of  inflammatory  processes.  To  exemplify,
MMP-9,  released  by  monocyte-macrophages, plays
an important role  in  inflammatory  processes such
as  atherosclerosis  development  and  plaque  rupture
[9]. Genetic analyses have shown that  polymorphisms
in  the  MMP-9  gene are  related  to  the  presence
and  severity  of  atherosclerosis  [31].
Our  results  showed  that  pretreatment  with
adenosine  attenuated  the  angiotensin  II-stimulated
increase in phospho-p38. The attenuation was
statistically significant  for  phospho-NF-κB and
phospho-JNK. This finding is consistent  with  an
earlier  report by Fotheringham  et al. [17]. They
indicated  that  inhibition  of  TNF-α  release  by  U-
937  cells  might  be  mediated  via  decreasing  p38
activity  and  TNFα  mRNA  instability.  In  another
study,  pretreatment  of  HT-29  cells  with  adenosine
resulted  in  reduced  p38  and  JNK  phosphorylation
followed  by  TNFα  treatment  [27].  The  employed
ELISA  kit  detects phosphorylated  p65  subunit
(RelA)  of NF-κB complex.  Phosphorylation  of  p65
indicates  that  NF-κB  is  activated  by  the  classical
pathway utilizing IκB phosphorylation and
degradation.  However,  angiotensin  II  treatment  did
not  significantly  augment  IκB  phosphorylation.  This
observation could partly be explained by fast
proteosomal  degradation  of  phosphorylated  IκB.
Furthermore,  alternative  mechanisms  could  be
assumed  to  account  for  NF-κB  activation  such  as
MAP  kinase,  Rho  kinase  and  calcium  dependent
pathways  [32, 33].  In  our  study,  adenosine  could
not  significantly  inhibit  angiotensin  II-activated  NF-
κB.  This  can  be  interpreted  by  the  finding  that
NF-κB  inhibition  by  adenosine  is  mediated  by
cAMP  response  element  binding  protein  (CREB).
Adenosine activates CREB transcription factor in a
cAMP/PKA  dependent  manner. Activated  CREB
competes  with  NF-κB  for  the  co-activator,  CBP,
which  results  in  decreased  NF-κB  transcriptional
activity  [34].  However,  suppression  of  NF-κB  by
adenosine  through  cAMP/PKA  and  IκB  modulation
has been  shown  previously  [35].
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Most  of  anti-inflammatory  effects  of  adenosine
have been assigned to its  A2A  receptor.  The  inhibitory
effects of  A2A receptors on  immune and inflammatory
processes in monocytes and  macrophages have  been
shown  to  occur primarily via  cAMP/PKA  pathway
[27, 36].  This  is  in  agreement  with  our  finding
that  H89  pre-incubation reversed the  inhibitory  effect
of adenosine  on  angiotensin  II-induced p38. Down-
regulation of p38 by adenosine treatment prior to
angiotensin II,  was not in accordance with down-
regulation of  MMP-9. It could be postulated that
p38  activation was not implicated in angiotensin
II-mediated MMP-9  expression.
In conclusion,  our  data  provide  further  evidence
to show that  monocytic  MMP-9  is  a  major  target
gene  for  angiotensin  II,  presumably  leading  to  its
deleterious  effects.  Adenosine  pretreatment did  not
inhibit the increased MMP-9 production  in  response
to  angiotensin  II.  However,  it  showed  a  potential
to  modulate  specific  signaling  mediators  induced
by angiotensin II,  in which  PKA  has  a  pivotal  role.
Further investigations are required to elucidate
the  efficacy of  adenosine against “angiotensin  II
world”.
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